Dewmar International says that it has filed a provisional patent application titled “Cannabinoid Formulation to Treat Lung Cancer” with the United States Patent and Trademark Office (USPTO). The companies current brands include “Kush Cakes” psychedelic brownies and “Canna Energy” hemp drinks.
According to Dewmar, “The invention relates to an inhalation pharmaceutical formulation of metered and/or titrated doses of certain types of cannabinoids to treat lung cancer using either a pressurized inhaler or a dry powder inhaler. The invention also pertains to the pharmaceutically acceptable derivatives of the compounds of the invention, to processes for the preparation of these compounds, to chemical intermediates useful in preparation of these compounds, to a method of combating cancerous tumors in a mammal, and to pharmaceutical compositions containing these compounds or their derivatives.”
The company added that “Dewmar International has already recruited a team of research physicians, including oncology specialists, to test this invention in the near future. They continue to recruit both oncologists and respiratory therapists.”
Dewmar CEO Marco Moran said, “Our premise is simple; we asked this basic question: ‘How many routine or chronic marijuana smokers do you know that have ever been diagnosed with lung cancer?’ No one could really come back with a single patient of record. Cannabinoids have the potential to be one of the most effective treatments of lung cancer ever introduced to oncologists. We have taken this medical hypothesis one step further to deliver these chemicals in a metered, controlled dose which is what medical doctors are seeking.”
Moran said that he had experience as a former Director of Pharmacy and Regulatory Affairs for inhaled nitric oxide company INO Therapeutics, later Ikaria, saying, “I traveled from state to state with our quality assurance team to assure the proper set up and implementation of our innovative inhalation systems. I learned many state-of-the-art inhalation dosing forms and techniques from this forward-thinking company who was in the process of trying to create an ‘inhalation Viagra’ that could work in a matter of seconds as opposed to minutes. INO is the entity that helped expand my creativity when it came to new product development and implementation; they encouraged me to think outside of the box. This invaluable experience with INO has perfectly positioned me to maximize my talents to take Dewmar to greater heights than I could have ever imagined.”
The announcement says that “Dr. Moran played an integral role in the early 2000s in working with the company’s France headquarters to spread these life-saving inhalation therapies across many neonatal intensive care units (ICUs) across the United States.”
According to a 2011 SEC document filed by Dewmar, Moran worked for INO Therapeutics for a year during the same time period that he owned a “seasonal chain of sno-ball stands on popular street corners and in at local area malls.” According to the document, “He then moved to more challenging and higher paying staff pharmacist positions at hospital settings in the state of Mississippi.”
Read the Dewmar International press release.
